Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Abbott

This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

Barchart · Dec 23, 2025

Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength

Broadcom, Abbott, and Nordic American raised dividends, offering strong yields and long-term upside despite market volatility and sector headwinds.

MarketBeat · Dec 22, 2025

Abbott Elementary's Mid-Season Finale Featured Its Craziest Plot Twist, And I Can't Stop Thinking About The Silly Repercussions It Could Have

I cannot believe this really happened!

Cinemablend · Dec 11, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Benzinga · Dec 5, 2025

Faulty glucose monitors linked to 7 deaths and more than 700 injuries worldwide. Here’s what we know

The sensors provide real-time measurements of sugar levels in the blood, sending that data wirelessly to a device or phone.

Euronews · Dec 5, 2025

Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns

The U.S. Food and Drug Administration warned people to stop using certain types of glucose monitor sensors that were linked to seven deaths

The Independent UK · Dec 4, 2025

7 deaths linked to faulty glucose monitors put in people’s arms, FDA says

About three million devices are affected, though many may be expired or already used

The Independent UK · Dec 3, 2025

Read news from The Economist, FT, and more,
with one subscription

Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Barchart · Nov 26, 2025

How This 'Hidden Gold Mine' Has Beaten The Market For 30 Years

For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes.

Benzinga · Nov 24, 2025

Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle

For the previous edition of Deal Dispatch, click here.

Benzinga · Nov 21, 2025

Our fashion team has been hunting Black Friday fashion deals for years – here are the 24 items we really rate

Plenty of brands have already dropped major Black Friday discounts, and these are items worth shopping right now

Woman & Home · Nov 21, 2025

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Barchart · Nov 20, 2025

Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

International Business Times UK · Nov 20, 2025

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Benzinga · Nov 20, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Cinemablend · Nov 15, 2025

The Paper Is A Blast, And I Want A Specific Crossover With Abbott Elementary

Hear me out.

Benzinga · Nov 10, 2025

The Insider Report: The Bears Have Been Poked – Will They Fall Back Asleep?

Stocks dropped hard last week, but a late-day rally on Friday staved off the worst. The Dow Jones Industrial Average held up the best, only closing down 1.21%. The SP 500 was down 1.63%, but the Nasdaq suffered the most, as it closed down 3.04%. Tech was routed hard as…

The Independent UK · Nov 9, 2025

Preliminary tests find germ that causes botulism in ByHeart baby formula

California health officials say tests showed that ByHeart baby formula linked to a botulism outbreak contained the type of bacteria that produces the toxin that has sickened at least 13 infants in 10 states

Barchart · Nov 6, 2025

Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Oct 17, 2025

5 Dividend Aristocrats Proving That Reliability Still Pays in 2025

These five companies offer stability in terms of growth and income.

MarketBeat · Oct 17, 2025

Abbott Laboratories' October Price Plunge Is a Signal to Buy

Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.

Benzinga · Oct 16, 2025

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance.

Benzinga · Oct 16, 2025

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.

Benzinga · Oct 15, 2025

Abbott Tightens Annual Sales Forecast As Q3 Sales Miss Expectations

Abbott Laboratories (NYSE:ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.

Cinemablend · Oct 2, 2025

Abbott Elementary's Season 5 Premiere Had A Lot Of Moving And Shaking, And I Need To Talk About One Specific Change

Well, this will be fun!

Barchart · Sep 29, 2025

What to Expect From Abbott Laboratories' Next Quarterly Earnings Report

Abbott Laboratories will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.